^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TRAIL R2 agonist

    Related drugs:
    Apply
    A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    12/09/2022
    Initiation :
    03/20/2017
    Primary completion :
    01/21/2022
    Completion :
    01/21/2022
    KRAS
    |
    KRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)
    Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma (NCT02983006)
    Phase 1
    NYU Langone Health
    Completed
    Last update posted :
    10/18/2021
    Initiation :
    10/01/2016
    Primary completion :
    12/23/2019
    Completion :
    01/01/2021
    IL2
    |
    Opdivo (nivolumab) • DS-8273
    CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer (NCT01033240)
    Phase 2
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    07/09/2010
    Primary completion :
    07/13/2012
    Completion :
    09/09/2013
    AFP
    |
    sorafenib • tigatuzumab (CS-1008)
    A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02558140)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/04/2018
    Initiation :
    10/11/2015
    Primary completion :
    11/06/2017
    Completion :
    11/06/2017
    FAP
    |
    FAP expression
    Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (NCT01307891)
    Phase 2
    University of Alabama at Birmingham
    Completed
    Last update posted :
    10/26/2017
    Initiation :
    03/01/2011
    Primary completion :
    06/01/2016
    Completion :
    06/01/2017
    HER-2 • PGR
    |
    HER-2 amplification • HER-2 negative
    |
    albumin-bound paclitaxel • tigatuzumab (CS-1008)
    A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) (NCT00517049)
    Phase 2
    Genentech, Inc.
    Completed
    Last update posted :
    06/06/2017
    Initiation :
    03/01/2008
    Primary completion :
    12/01/2009
    Completion :
    12/01/2009
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • drozitumab (RG7425)
    A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection (NCT03083743)
    Phase 3
    Shanghai Gebaide Biotechnology Co., Ltd.
    Unknown status
    Last update posted :
    03/20/2017
    Initiation :
    10/01/2016
    Primary completion :
    10/01/2017
    Completion :
    06/01/2018
    ALK
    |
    EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative
    |
    dulanermin (AMG 951)
    Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (NCT01940172)
    Phase 1b
    TetraLogic Pharmaceuticals
    Completed
    Last update posted :
    01/14/2016
    Initiation :
    11/01/2013
    Primary completion :
    09/01/2015
    Completion :
    12/01/2015
    MUC16
    |
    birinapant (IGM-9427) • conatumumab (AMG 655)